Tag: Horizon Therapeutics

June 3, 2020 Off

Data Presented on KRYSTEXXA® (pegloticase injection) Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach

By BusinessWire

KRYSTEXXA

June 20, 2019 Off

Horizon Therapeutics evaluates Krystexxa in combination with methotrexate to increase response rates and duration of therapy

By BusinessWire

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.